Carmot Therapeutics, Inc.
NEWS
After a slow start to 2023 in an uncertain economic climate, biopharma mergers and acquisitions are on the rise.
Armed with a pipeline of obesity and diabetes hopefuls, Carmot Therapeutics joins the small group of biotechs to attempt a Nasdaq debut this year.
Money on the Move: A weekly roundup of notable funding news across biopharma industry. See who raked in funds for which diseases
Gilead was interested in Cell Design Labs for its technology around bi-specific antigen recognition and its “Throttle” technology.
Under the deal, Carmot will use its lead-identification technology to identify and advance novel drug leads for Parkinson’s disease and other disease areas.
JOBS
IN THE PRESS